Table 1 Details of the characteristics of the eligible patients (n = 86)
|  | N = 86 (%) |
|---|---|
Gender | |
 Male | 76 (88.4) |
 Female | 10 (11.6) |
Age | 45 (20–70) |
Pathology | |
 WHO II | 13 (15.1) |
 WHO III | 73 (84.9) |
T stage | |
 T1 | 8 (9.3) |
 T2 | 29 (33.7) |
 T3 | 30 (34.9) |
 T4 | 19 (22.1) |
N stage | |
 N1 | 10 (11.6) |
 N2 | 39 (45.3) |
 N3 | 37 (43.1) |
Metastatic organ | |
 Bone | 61 (70.9) |
 Liver | 21 (24.4) |
 Lung | 8 (9.3) |
 Node | 23 (26.7) |
Metastatic sites | |
 Single | 64 (74.4) |
 Multiple | 22 (25.6) |
EBV-DNA (copies/ml) | |
 < 500 | 5 (5.8) |
 > 500 | 25 (29.1) |
 Missing | 56 (65.1) |
Lactate dehydrogenase (U/L) | |
 < 250 | 55 (63.9) |
 ≥ 250 | 31 (36.1) |
PET/CT SUVmax | |
 Primary tumor | 11.4 (3.7–35.7) |
 Lymph node | 11.3 (2.3–36.1) |
 Metastatic site | 9.25 (2–20.6) |
  Bone | 8.8 (2–20.6) |
  Liver | 7.9 (4.4–20.5) |
  Lung | 7.9 (2–10.6) |
  Node | 9.25 (2–20.6) |
Treatment | |
 PCT + RT | 70 (81.4) |
 PCT + CCRT | 16 (18.6) |
Response to CT (primary tumor) | |
 Complete response (CR) | 2 (2.3) |
 Partial response (PR) | 75 (87.2) |
 Stable disease (SD) | 6 (7.0) |
 Progression disease (PD) | 3 (3.5) |
Response to CT (metastatic site) | |
 CR | 3 (3.5) |
 PR | 23 (90.5) |
 SD | 10 (90.5) |
 PD | 4 (9.54) |
 Not reported | 46 (9.54) |